Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2008

View Archived Issues

ViroPharma to acquire Lev under merger agreement

Topical PSD-503 safe and effective for the treatment of stress urinary incontinence

ABT-925 demonstrates regionally selective dopamine D3 occupancy in humans

MGN-1703 begins phase I cancer study

Erbitux approved in Japan for metastatic colorectal cancer

Enrollment progresses in phase II RA study of CH-1504

Provenge studied in localized prostate cancer patients prior to surgery

JN-403, a novel alpha7 nAch receptor profiled at Novartis

Sublingual buprenorphine safe and effective in controlling neonatal abstinence syndrome

Triolex studied in new phase II trial for type 2 diabetes

Recent Dainippon Sumitomo patent describes new analgesic agents

Novel antiinflammatory agents claimed in recent patent literature

Preclinical studies at Karo Bio support the use of ERbeta agonists in treating depression

Sym-001 studied in new phase II trial for ITP

Alzheimer's drug candidate MCD-386 begins phase I trial

Prulifloxacin demonstrates utility in infectious diarrhea

Recent patents disclose new compounds for sleep disorders, anxiety disorders and schizophrenia

Suspension of phase II trial of doxorubicin Transdrug

Japanese approval for Biopten in PKU

Enrollment under way in phase III laquinimod study in RRMS

Enrollment completed in phase I study of Alzheimer's vaccine Affitope AD-01

SPA agreement for LibiGel FSD program in naturally menopausal women

Metabolon expands multistudy agreement with Mitsubishi Tanabe Pharma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...